Drugs / C-CAR031
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07444281 | Dec 2024 → Apr 2027 expected | squamous cell lung carcinoma | Shanghai AbelZeta Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05155189 | Feb 2022 → May 2026 overdue | hepatocellular carcinoma | Zhejiang University | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06590246 | Sep 2024 → Apr 2030 expected | hepatocellular carcinoma | Shanghai AbelZeta Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C-CAR031 | “Patients in the dose escalation section will receive autologous C-CAR031 via intravenous (IV) infusion at DL1 and DL2.” NCT06590246 ↗ |
| Modality | Cell therapy | “armored CART cell injection” NCT05155189 ↗ |
| Route | Intravenous | “Autologous C-CAR031 administered by intravenous (IV) infusion” NCT05155189 ↗ |
| Target | GPC3 | “Targeting GPC3 armored CART cell injection (C-CAR031)” NCT05155189 ↗ |